- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01876589
Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion:a Randomized H215O PET/CT Study (VANISH)
Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: a Randomized H215O PET/CT Study
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Objective The objective of the proposed study is to determine the impact of VRT, in comparison with conventional drug-eluting stenting, on endothelium dependent vasodilation and maximal hyperemic myocardial perfusion using H215O PET.
Study design The study is designed as a single center single-blind randomized clinical trial and will be conducted at the VU University Medical Center in Amsterdam.
Summary of the study design It is hypothesized that VRT will result in augmented endothelium dependent coronary vasodilation and maximal myocardial perfusion as compared with conventional stenting of a coronary lesion. Within one year sixty patients (age 18-65) with documented single vessel CAD (type A or B1 lesion) accepted for PCI based on clinical grounds and according to current international guidelines, will be asked to participate in this trial. Patients will be randomized to implantation of a drug-eluted stent (Xience Prime) or BRS (Absorb). The patients will be blinded to the nature of the implanted device. H2 15O PET will be performed one month (reference scan), one year, and three years after the PCI procedure (resolution of BRS is generally complete within a three year period). The PET protocol will consist of three MBF measurements: resting MBF, during endothelial dependent vasodilation provoked by coldpressor-testing (CPT), and during (endothelial dependent and independent) maximal vasodilation by infusion of adenosine intravenously. After three years a control invasive coronary angiogram will document any potential obstructive coronary lesions that may affect the MBF measurements.
Primary study parameters/outcome of the study MBF measurements: resting MBF, during endothelial dependent vasodilation provoked by cold-pressor-testing (CPT), and during (endothelial dependent and independent) maximal vasodilation by infusion of adenosine intravenously
Secondary study parameters/outcome of the study Obstructive coronary lesions on control invasive coronary angiogram that may affect the MBF measurements.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Nederland, 1081 HV
- VU University Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients with documented obstructive CAD by invasive coronary angiography resulting in myocardial ischemia (either documented by invasive (i.e. fractional flow reserve, FFR) or noninvasive imaging techniques (e.g. exercise ECG, myocardial perfusion imaging, or inducibility of wall motion abnormalities during dobutamine stress).
- Presence of a single, de-novo lesion in a native coronary artery (type A or B1), with a reference vessel diameter of at least 3.0 mm and a diameter stenosis of 50% or more and less than 100%, with a thrombolysis in myocardial infarction (TIMI) flow grade of at least 2. Coronary lesion must be amendable for successful treatment with one of the following BRS device dimensions: length 18 or 28 mm, diameter 3.0 or 3.5 mm.
Exclusion Criteria:
- age of 65 or above
- refusal or inability to provide written informed consent
- other than single CAD
- abnormal echocardiographic findings (i.e. wall motion abnormalities, ventricular hypertrophy, valvular disease etc.)
- complex coronary lesion characteristics (e.g. lesions located in the left main coronary artery, lesions involving a side branch more than 2 mm in diameter, and the presence of thrombus or another clinically significant stenosis in the target vessel)
- poor kidney function defined as an eGFR < 30 ml/min
- astma or chronic obstructive pulmonary disease
- other than sinus rhythm
- pregnancy
- bail out stenting after placement of the study device
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Bioresorbable vascular scaffold
Paritcipants will receive a bioresorbable vascular scaffols (BVS)
|
Drug eluting coronary stent, resorbable in 2-3 years
|
Actieve vergelijker: Xience Prime
Participant will receive a Xience Prime stent
|
Drug eluting metallic stent
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Evaluation of Myocardial Blood Flow over time
Tijdsspanne: Three years
|
Endothelial dependent vasomotor function and effect on myocardial perfusion
|
Three years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Restenosis
Tijdsspanne: Three years
|
Obstructive coronary lesions and lumen dimensions on control invasive coronary angiogram that may affect the MBF measurements
|
Three years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Paul Knaapen, MD, PhD, Amsterdam Umc, Location Vumc
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- VANISH
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Coronaire hartziekte
-
Lawson Health Research InstituteVoltooidArteriosclerose van Arterial Coronary Artery Bypass GraftCanada
-
Deutsches Herzzentrum MuenchenVoltooidArteriosclerose van Arterial Coronary Artery Bypass GraftDuitsland
-
University Hospital, AngersWervingPopliteale slagaderbeknellingFrankrijk
-
University Hospital, AngersVoltooidPoplitea Entrapment SyndroomFrankrijk
-
Stanford UniversityIngetrokkenPoplitea Artery Entrapment Syndroom | Functioneel beknellingssyndroom van de arteria popliteaVerenigde Staten
-
University Hospital, Strasbourg, FranceWervingEpistaxis, Anterior Ethmoid ArteryFrankrijk
-
Resicardunion nationale de formation et d'evaluation en medecine cardio-vasculaireVoltooidHartfalen | Acute kransslagader syndroom | Coronaire Bypass Graft Stenose van Native Artery GraftFrankrijk
Klinische onderzoeken op Bioresorbable vascular scaffold
-
Abbott Medical DevicesVoltooid
-
Meril Life Sciences Pvt. Ltd.OnbekendCoronaire hartziekteMaleisië, Brazilië, Indonesië, Macedonië, de Voormalige Joegoslavische Republiek
-
Shanghai MicroPort Medical (Group) Co., Ltd.Voltooid
-
University Hospital, ToulouseBoston Scientific CorporationVoltooidAcute kransslagader syndroomFrankrijk
-
Elixir Medical CorporationEuropean Cardiovascular Research CenterBeëindigd
-
International Foundation for Development of Medical...KCRIVoltooid
-
Elixir Medical CorporationVoltooidCoronaire hartziekteNieuw-Zeeland, België
-
Deutsches Herzzentrum MuenchenVoltooid
-
Elixir Medical CorporationVoltooidCoronaire hartziekteBelgië, Brazilië
-
Amaranth Medical Inc.OnbekendMyocardiale ischemie | Coronaire hartziekteColombia, Italië